HRP20170791T1 - Smjesa rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil]-fosfata - Google Patents

Smjesa rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil]-fosfata Download PDF

Info

Publication number
HRP20170791T1
HRP20170791T1 HRP20170791TT HRP20170791T HRP20170791T1 HR P20170791 T1 HRP20170791 T1 HR P20170791T1 HR P20170791T T HRP20170791T T HR P20170791TT HR P20170791 T HRP20170791 T HR P20170791T HR P20170791 T1 HRP20170791 T1 HR P20170791T1
Authority
HR
Croatia
Prior art keywords
alaninyl
benzyloxy
phenyl
gemcitabine
phosphate
Prior art date
Application number
HRP20170791TT
Other languages
English (en)
Inventor
Christopher Mcguigan
Fabrizio PERTUSATI
Original Assignee
University College Cardiff Consultants Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49622844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20170791(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1220666.0A external-priority patent/GB201220666D0/en
Priority claimed from GB201307314A external-priority patent/GB201307314D0/en
Application filed by University College Cardiff Consultants Limited filed Critical University College Cardiff Consultants Limited
Publication of HRP20170791T1 publication Critical patent/HRP20170791T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/06—Halogens; Compounds thereof
    • B01J27/128—Halogens; Compounds thereof with iron group metals or platinum group metals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01S—DEVICES USING THE PROCESS OF LIGHT AMPLIFICATION BY STIMULATED EMISSION OF RADIATION [LASER] TO AMPLIFY OR GENERATE LIGHT; DEVICES USING STIMULATED EMISSION OF ELECTROMAGNETIC RADIATION IN WAVE RANGES OTHER THAN OPTICAL
    • H01S5/00—Semiconductor lasers
    • H01S5/30—Structure or shape of the active region; Materials used for the active region
    • H01S5/34—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers
    • H01S5/343—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser
    • H01S5/34326—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser with a well layer based on InGa(Al)P, e.g. red laser

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Claims (12)

1. Gemcitabin-[fenil-(benziloksi-L-alaninil)]-fosfat u obliku smjese gemcitabin-[fenil-(benziloksi-L-alaninil)]-(S)-fosfata: [image] i gemcitabin-[fenil-(benziloksi-L-alaninil)]-(R)-fosfata: [image] gdje odnos (S) epimera prema (R) epimeru je najmanje 20:1.
2. Gemcitabin-[fenil-(benziloksi-L-alaninil)]-fosfat u skladu s patentnim zahtjevom 1, koji je 100% gemcitabin-[fenil-(benziloksi-L-alaninil)]-(S)-fosfat: [image]
3. Gemcitabin-[fenil-(benziloksi-L-alaninil)]-fosfat u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, za liječenje karcinoma.
4. Gemcitabin-[fenil-(benziloksi-L-alaninil)]-fosfat za upotrebu u skladu s patentnim zahtjevom 3, gdje je karcinom solidni karcinom.
5. Gemcitabin-[fenil-(benziloksi-L-alaninil)]-fosfat za upotrebu u skladu s patentnim zahtjevom 4, gdje je solidni karcinom odabran iz karcinoma dojke, debelog crijeva i prostate.
6. Farmaceutski pripravak koja sadrži gemcitabin-[fenil-(benziloksi-L-alaninil)]-fosfat u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2 zajedno s farmaceutski prihvatljivim nosačem, razblaživačem ili ekscipijensom.
7. Farmaceutski pripravak u skladu s patentnim zahtjevom 6 za intravensku uporabu.
8. Farmaceutski pripravak u skladu s patentnim zahtjevom 7, gdje pripravak sadrži sterilnu vodenu otopinu.
9. Farmaceutski pripravak u skladu s patentnim zahtjevom 8, gdje je vodena otopina Ringer-ova otopina ili izotonični natrij klorid.
10. Pripravak u skladu s bilo kojim od patentnih zahtjeva 6 do 9, gdje je pripravak za liječenje karcinima.
11. Pripravak za uporabu u skladu s patentnim zahtjevom 10, gdje je karcinom solidni karcinom.
12. Pripravak za uporabu u skladu s patentnim zahtjevom 11, gdje je solidni karcinom odabran iz karcinoma dojke, debelog crijeva i prostate.Postotak
HRP20170791TT 2012-11-16 2017-05-29 Smjesa rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil]-fosfata HRP20170791T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1220666.0A GB201220666D0 (en) 2012-11-16 2012-11-16 Process for preparing chemical compounds
GB201307314A GB201307314D0 (en) 2013-04-23 2013-04-23 Process for preparing chemical compounds
EP16195036.5A EP3150616B1 (en) 2012-11-16 2013-11-15 Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate

Publications (1)

Publication Number Publication Date
HRP20170791T1 true HRP20170791T1 (hr) 2017-08-25

Family

ID=49622844

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20170791TT HRP20170791T1 (hr) 2012-11-16 2017-05-29 Smjesa rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil]-fosfata
HRP20190831TT HRP20190831T1 (hr) 2012-11-16 2019-05-06 Mješavina rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil)]-fosfata

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20190831TT HRP20190831T1 (hr) 2012-11-16 2019-05-06 Mješavina rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil)]-fosfata

Country Status (28)

Country Link
US (3) US10005810B2 (hr)
EP (3) EP3235824B1 (hr)
JP (5) JP2016506371A (hr)
KR (1) KR20150103669A (hr)
CN (2) CN111592577A (hr)
AU (1) AU2013346515B2 (hr)
CA (1) CA2891266C (hr)
CL (1) CL2015001307A1 (hr)
CY (2) CY1119161T1 (hr)
DK (2) DK3150616T3 (hr)
EA (1) EA028871B1 (hr)
ES (3) ES2725491T3 (hr)
HK (1) HK1210784A1 (hr)
HR (2) HRP20170791T1 (hr)
HU (2) HUE044605T2 (hr)
IL (1) IL238792A (hr)
IN (1) IN2015DN04090A (hr)
LT (2) LT3235824T (hr)
MX (1) MX2015006195A (hr)
MY (1) MY176133A (hr)
NZ (1) NZ708177A (hr)
PH (1) PH12015501090A1 (hr)
PL (2) PL3150616T3 (hr)
PT (2) PT3150616T (hr)
RS (2) RS56038B1 (hr)
SG (3) SG10201510324YA (hr)
SI (2) SI3235824T1 (hr)
WO (1) WO2014076490A1 (hr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
SI3235824T1 (sl) 2012-11-16 2019-08-30 University College Cardiff Consultants Limited Zmes rp / sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
US10030044B2 (en) 2013-11-27 2018-07-24 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
CN105153257B (zh) * 2014-06-12 2019-03-05 正大天晴药业集团股份有限公司 索非布韦的制备方法
MX2020004054A (es) 2014-06-25 2021-11-30 NuCana plc Formulacion que comprende un profarmaco de gemcitabina.
RS60968B1 (sr) * 2014-06-25 2020-11-30 NuCana plc Prolekovi gemcitabina
CN105254694B (zh) * 2014-07-14 2018-11-27 正大天晴药业集团股份有限公司 氘代核苷衍生物
JP6646663B2 (ja) 2014-07-22 2020-02-14 ニューカナ バイオメッド リミテッドＮｕｃａｎａ Ｂｉｏｍｅｄ Ｌｉｍｉｔｅｄ ゲムシタビン−［フェニル（ベンゾキシ−ｌ−アラニニル）］ホスフェートの製造方法リン酸誘導体を製造する方法
JP2017522343A (ja) * 2014-07-31 2017-08-10 サンド・アクチエンゲゼルシヤフト ホスホルアミデート類の合成
WO2016033164A1 (en) 2014-08-26 2016-03-03 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CN105461774B (zh) * 2014-09-30 2020-11-24 江苏豪森药业集团有限公司 索非布韦的制备方法
CN105461773B (zh) * 2014-09-30 2020-12-01 江苏豪森药业集团有限公司 索非布韦的制备方法及其中间体
GB201417644D0 (en) * 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
US9718851B2 (en) 2014-11-06 2017-08-01 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
UA124966C2 (uk) 2015-03-06 2021-12-22 Атеа Фармасеутікалс, Інк. <font face="Symbol">b</font>-D-2'-ДЕЗОКСИ-2'-<font face="Symbol">a</font>-ФТОР-2'-<font face="Symbol">b</font>-C-ЗАМІЩЕНІ-2-МОДИФІКОВАНІ-N<sup>6</sup>-ЗАМІЩЕНІ ПУРИНОВІ НУКЛЕОТИДИ ДЛЯ ЛІКУВАННЯ ВИКЛИКАНИХ HCV ЗАХВОРЮВАНЬ
US10407456B2 (en) 2015-03-26 2019-09-10 Quimica Sintetica, S.A. Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof
CN106397515B (zh) * 2015-07-28 2021-05-11 广东东阳光药业有限公司 一种改良的索菲布韦制备方法
CN106543220A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
CN112156102B (zh) * 2015-09-16 2023-10-03 济南高合医疗科技有限公司 一种nuc-1031单一异构体的晶型及其制备方法
US10660912B2 (en) 2015-10-05 2020-05-26 NuCana plc Combination therapy for cancer
WO2017090264A1 (ja) * 2015-11-27 2017-06-01 大原薬品工業株式会社 ５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル
MY196772A (en) * 2015-12-11 2023-05-03 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
GB201522771D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
US10239910B2 (en) * 2016-07-20 2019-03-26 Optimus Drugs (P) Limited Process for the preparation of sofosbuvir
WO2018019188A1 (zh) * 2016-07-23 2018-02-01 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的多晶型及其制备方法
EP3865136A1 (en) 2016-09-07 2021-08-18 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for corona virus treatment
US10266558B2 (en) * 2016-10-07 2019-04-23 Alexandre Vasilievich Ivachtchenko Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
CN109863160B (zh) * 2016-12-23 2022-06-07 四川科伦博泰生物医药股份有限公司 核苷磷酸类化合物及其制备方法和用途
KR20230151050A (ko) 2017-02-01 2023-10-31 아테아 파마슈티컬즈, 인크. C형 간염 바이러스를 치료하기 위한 뉴클레오티드 헤미-술페이트 염
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
TW202012001A (zh) 2018-04-10 2020-04-01 美商亞堤製藥公司 C型肝炎病毒(hcv)感染硬化之患者的治療
EP3808752A4 (en) 2018-06-12 2022-03-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. PHOSPHONYMIDE ESTER COMPOUND, SALT THEREOF, RELATIVE CRYSTAL FORM THEREOF, PROCESS FOR THEIR PREPARATION AND THEIR USE
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
RU2740058C1 (ru) * 2020-06-26 2020-12-31 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения софосбувира и фосфорамидаты
CN112409431B (zh) * 2020-12-07 2023-04-21 武汉伯瑞恒医药科技有限公司 阿糖胞苷结构类似物及其制备方法和用途
CN113549076B (zh) * 2021-07-23 2022-12-06 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US6346627B1 (en) 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
DK1045897T3 (da) 1998-01-23 2002-05-13 Newbiotics Inc Enzymatisk katalyserede, terapeutiske midler
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
WO2003068162A2 (en) 2002-02-14 2003-08-21 Pharmasset Ltd. Modified fluorinated nucleoside analogues
EP1567169A4 (en) 2002-11-04 2009-10-21 Xenoport Inc GEMCITABINE PROMOTERS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
CA2618335C (en) * 2005-08-15 2015-03-31 F.Hoffmann-La Roche Ag Antiviral phosphoramidates of 4'-substituted pronucleotides
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
PA8852101A1 (es) * 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
MX2011007364A (es) 2009-01-09 2012-02-28 Univ Cardiff Derivados de fosforamidato de compuestos de nuecleosido de guanosina para tratamiento de infecciones virales.
TWI598358B (zh) * 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
JP5872539B2 (ja) * 2010-03-31 2016-03-01 ギリアド ファーマセット エルエルシー プリンヌクレオシドホスホルアミダート
BR112013001267A2 (pt) * 2010-07-19 2016-05-17 Gilead Sciences Inc métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro
CA2810928A1 (en) * 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
CA2819041A1 (en) * 2010-12-22 2012-06-28 Alios Biopharma, Inc. Cyclic nucleotide analogs
WO2012117246A1 (en) * 2011-03-01 2012-09-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer
KR20200006177A (ko) * 2011-03-02 2020-01-17 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
SG11201401499XA (en) * 2011-10-14 2014-09-26 Stc Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
SI3235824T1 (sl) * 2012-11-16 2019-08-30 University College Cardiff Consultants Limited Zmes rp / sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
TW201542578A (zh) * 2013-06-26 2015-11-16 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
ES2927955T3 (es) 2013-09-11 2022-11-14 Univ Emory Composiciones de nucleótidos y nucleósidos y sus usos
TW201524990A (zh) * 2013-10-11 2015-07-01 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
US10030044B2 (en) 2013-11-27 2018-07-24 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
CN106029060A (zh) * 2013-11-27 2016-10-12 美国卫生和人力服务部 哌啶和哌啶衍生物及其在治疗病毒感染和癌症中的用途
RS60968B1 (sr) 2014-06-25 2020-11-30 NuCana plc Prolekovi gemcitabina
MX2020004054A (es) 2014-06-25 2021-11-30 NuCana plc Formulacion que comprende un profarmaco de gemcitabina.
JP6646663B2 (ja) 2014-07-22 2020-02-14 ニューカナ バイオメッド リミテッドＮｕｃａｎａ Ｂｉｏｍｅｄ Ｌｉｍｉｔｅｄ ゲムシタビン−［フェニル（ベンゾキシ−ｌ−アラニニル）］ホスフェートの製造方法リン酸誘導体を製造する方法
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
KR20180021697A (ko) 2015-05-14 2018-03-05 뉴카나 피엘씨 암 치료
US10660912B2 (en) 2015-10-05 2020-05-26 NuCana plc Combination therapy for cancer
MY196772A (en) 2015-12-11 2023-05-03 NuCana plc Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
MD3393478T2 (ro) 2015-12-23 2020-04-30 NuCana plc Terapie combinată
US20190381084A1 (en) 2015-12-23 2019-12-19 Nucana Biomed Limited Combination therapy
GB201713914D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Combination therapy

Also Published As

Publication number Publication date
CA2891266A1 (en) 2014-05-22
CN104903339A (zh) 2015-09-09
JP2016506371A (ja) 2016-03-03
IL238792A0 (en) 2015-06-30
BR112015011155A2 (pt) 2017-07-11
HRP20190831T1 (hr) 2019-08-23
EA201590955A1 (ru) 2015-08-31
DK3150616T3 (en) 2017-06-06
EP3150616B1 (en) 2017-05-10
EP3235824B1 (en) 2019-03-27
ES2627195T3 (es) 2017-07-27
WO2014076490A1 (en) 2014-05-22
CN111592577A (zh) 2020-08-28
EP2920192A1 (en) 2015-09-23
PH12015501090B1 (en) 2015-07-27
PL3235824T3 (pl) 2019-09-30
JP2023052536A (ja) 2023-04-11
US10005810B2 (en) 2018-06-26
CA2891266C (en) 2020-12-08
JP2018009000A (ja) 2018-01-18
PT3150616T (pt) 2017-06-09
DK3235824T3 (da) 2019-05-20
JP2021020919A (ja) 2021-02-18
US11040997B2 (en) 2021-06-22
RS56038B1 (sr) 2017-09-29
US20220033433A1 (en) 2022-02-03
US20150291650A1 (en) 2015-10-15
CY1119161T1 (el) 2018-02-14
MX2015006195A (es) 2015-12-08
EP3235824A1 (en) 2017-10-25
KR20150103669A (ko) 2015-09-11
PL3150616T3 (pl) 2017-09-29
HK1210784A1 (en) 2016-05-06
IN2015DN04090A (hr) 2015-10-09
AU2013346515A1 (en) 2015-06-04
SG11201503750YA (en) 2015-06-29
HUE033335T2 (en) 2017-11-28
MY176133A (en) 2020-07-24
HUE044605T2 (hu) 2019-11-28
SG10201510324YA (en) 2016-01-28
CL2015001307A1 (es) 2015-12-11
ES2725491T3 (es) 2019-09-24
ES2618732T3 (es) 2017-06-22
RS58849B1 (sr) 2019-07-31
LT3150616T (lt) 2017-07-25
AU2013346515B2 (en) 2017-05-25
EP2920192B1 (en) 2017-02-22
LT3235824T (lt) 2019-07-10
PH12015501090A1 (en) 2015-07-27
SG10201510322UA (en) 2016-01-28
EP3150616A1 (en) 2017-04-05
CY1121663T1 (el) 2020-07-31
US20180273575A1 (en) 2018-09-27
PT3235824T (pt) 2019-05-30
JP2019196360A (ja) 2019-11-14
EA028871B1 (ru) 2018-01-31
IL238792A (en) 2017-09-28
NZ708177A (en) 2017-08-25
SI3235824T1 (sl) 2019-08-30
SI3150616T1 (sl) 2017-08-31

Similar Documents

Publication Publication Date Title
HRP20170791T1 (hr) Smjesa rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil]-fosfata
HRP20180007T1 (hr) Formulacija koja sadrži gemcitabin-predlijek
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
HRP20211177T1 (hr) Korteksolon 17alfa-valerat za uporabu u liječenju tumora
NZ710746A (en) Pyrrolobenzodiazepines and conjugates thereof
SG10201907684PA (en) Androgen receptor modulator and uses thereof
HRP20191919T1 (hr) Donori nitroksila sa poboljšanim terapijskim indeksom
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
ME01133B (me) Kombinovana terapija sa peptidnim epoksiketonima
TN2012000533A1 (en) New forms of rifaximin and uses thereof
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
MD20160016A2 (ro) Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin
JP2017530184A5 (hr)
MX2018016332A (es) Quimioterapias de combinacion.
TR201902057T4 (tr) Tetrasiklin bileşikleri.
MX2018003685A (es) Moleculas tipo esfingolipidos sinteticas, farmacos, metodos de su sintesis y metodos de tratamiento.
RU2014137190A (ru) Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение
CY1122357T1 (el) Αντικαρκινικος συνδυασμος που περιλαμβανει καμπαζιταξελη και σισπλατινη
HRP20210418T1 (hr) Liječenje s syd985 pacijenata s rakom koji ne reagira na t-dm1
WO2015009731A3 (en) Azacyclic constrained analogs of fty720
HRP20160387T1 (hr) Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
ZA201404068B (en) The use of silver(i) complexes as active pharmaceutical ingredients (api&#39;s) iincluding anticancer agents
BR112016017313A2 (pt) Composto, composição farmacêutica, inibidor da atividade da atpase de um complexo tip48/tip49, e, agentes antitumor e terapêutico para um tumor